American Marconi Wireless News - CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

NYSE - LSE

SCS	0.12%	16.14	$
CMSC	-0.52%	23.17	$
BCC	-3.92%	74.77	$
NGG	-0.37%	76.11	$
RYCEF	1.79%	15.68	$
CMSD	-0.13%	23.25	$
RIO	0.88%	78.32	$
GSK	0.66%	48.61	$
RELX	0.2%	40.73	$
RBGPF	0%	80.22	$
BCE	-0.04%	22.84	$
JRI	-0.37%	13.38	$
VOD	0.31%	12.84	$
BTI	-1.05%	56.45	$
AZN	0.82%	91.36	$
BP	1.86%	33.94	$

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

BOULEVARD 28.08.2025

SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM ET in New York City. CASI will also host one-on-one meetings with investors at the conference.

Text size:

A live webcast of the fireside chat will be available on the CASI Pharmaceuticals website at www.casipharmaceuticals.com under the "Investors" tab. A replay of the webcast will be available for 90 days after the live event.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) and plans to initiate the study in third quarter of 2025.

More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT:

Ingrid Choong, PhD
650-619-6115
[email protected]

SOURCE: CASI Pharmaceuticals

View the original press release on ACCESS Newswire

H.E.Young--AMWN

American Marconi Wireless News - CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Featured

Jailed Malaysian ex-PM Najib loses bid for house arrest

Australian state pushes tough gun laws, 'terror symbols' ban after shooting

Gang members given hundreds-years-long sentences in El Salvador

Gang members given hundred-years-long sentences in El Salvador